Jeremie Calais, MD, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, gives an overview of the study protocol for the Phase II PSMA-dRT trial (NCT04457245) of prostate-specific membrane antigen (PSMA) PET/CT before definitive radiation therapy for patients with intermediate- or high-risk prostate cancer. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
